查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2003036

伴侣动物疫苗市场：依动物类型、疫苗类型、给药途径及通路划分－2026-2032年全球市场预测

Companion Animal Vaccine Market by Animal Type, Vaccine Type, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，伴侣动物疫苗市场价值将达到 53.9 亿美元，到 2026 年将成长至 58.5 亿美元，到 2032 年将达到 95.4 亿美元，复合年增长率为 8.48%。

主要市场统计数据
基准年 2025 53.9亿美元
预计年份：2026年 58.5亿美元
预测年份：2032年 95.4亿美元
复合年增长率 (%) 8.48%

全面介绍不断发展的伴侣动物疫苗领域，探讨科学创新、饲主期望和临床实践变化之间的交汇点。

伴侣动物疫苗的现况正处于科学进展、饲主期望变化和临床实践发展三者交会的阶段。现代相关人员身处在一个预防医学理念和治疗方法创新共同塑造犬猫疫苗接种策略的环境，这影响着诊所的工作流程和供应链动态。兽医专业人员正日益将诊断筛检、个人化疫苗通讯协定和基于风险的建议融入日常诊疗，这促使生产商和经销商重新评估产品系列和传播策略。

详细概述了重塑伴侣动物疫苗的研发、交付和部署的关键技术、行为和临床变化。

伴侣动物疫苗领域正经历一场变革，其驱动力包括技术创新、消费者行为的改变以及监管和临床模式的演变。疫苗平台，特别是mRNA和重组技术的进步，正在开闢新的可能性，例如靶向免疫策略、更短的研发週期以及能够应对新出现的疾病威胁的高度适应性生产过程。这些科学进步正在重新定义产品蓝图，并促使现有製造商重新评估其研发重点和策略伙伴关係关係。

对 2025 年美国关税措施对伴侣动物疫苗的供应链、生产决策和通路经济的累积影响进行全面分析。

2025年，美国实施的关税措施进一步增加了伴侣动物疫苗生态系统中製造商、经销商和临床终端用户的复杂性。这些关税影响了进口原料、成品疫苗和专用设备的成本结构，从而改变了供应链决策，并促使企业重新评估製造地。一些相关人员加快了近岸外包的步伐，并相关人员供应商组合多元化，以降低贸易相关的成本波动风险。另一些利害关係人则寻求合约避险策略，以确保获得关键投入品。

可操作的细分情报揭示了动物类型、疫苗平台、给药途径和分销管道如何相互交织，从而塑造产品类型和商业化策略。

细分市场分析揭示了不同动物类型、疫苗平台、给药途径和分销管道的需求驱动因素、临床偏好和分销管道趋势的差异。就动物类型而言，猫和狗在流行病学和宠物饲养方面表现出不同的特征，这些特征会影响疫苗接种的优先顺序、接种计划和饲主的咨询。犬类疫苗接种策略通常专注于针对户外暴露和社交互动量身定制的核心疫苗和生活方式疫苗，而猫的疫苗接种通讯协定则优先考虑与室内/室外生活条件和多猫家庭动态相关的疾病风险。

从策略区域角度深入了解不同的管理体制、兽医基础设施和饲主行为如何导致世界各地市场出现不同的因应方式。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的临床实务规范、法律规范和商业性模式均有显着影响。在美洲，兽医基础设施和饲主参与模式支援多元化的分销管道，而强大的兽医医院网路和数位技术的广泛应用则促进了预防保健解决方案的分销和零售。相较之下，欧洲、中东和非洲的法规环境和经济状况环境各不相同，需要高度本地化的监管策略和灵活的分销模式，以适应成熟的兽医市场和新兴细分市场。

详细的竞争格局和生态系统评估揭示了成熟企业、生物技术创新者和服务供应商如何塑造其采用和商业化策略。

伴侣动物疫苗领域的竞争动态呈现出成熟企业、专业生技公司和新兴创新者并存的态势。成熟製造商继续利用其广泛的业务基础、与兽医专业人士的长期合作关係以及涵盖传统疫苗平台的丰富产品系列。这些优势支撑着规模化生产、可靠的分销管道和深厚的临床洞察力，从而能够与兽医网络和机构采购商建立并维持长期的合作关係。

为领导者提供清晰且优先的策略建议，重点在于平台多元化、供应链弹性、管道优化和临床证据的产生。

产业领导者应围绕四个相互关联的行动调整其策略重点：投资平台多元化、增强供应链韧性、优化通路策略以及深化临床合作。透过优先采用组合策略，平衡成熟的灭活疫苗和减毒活病毒疫苗与对mRNA、重组疫苗、次单元和类毒素技术的投资，企业可以同时满足当前的临床需求并应对未来的疾病威胁。此外，选择可扩展的生产合作伙伴并考虑区域生产能力，可以减轻贸易中断的影响，并支持快速的市场反应。

采用稳健的混合调查方法，结合对关键相关人员的访谈、整合第二手资料和交叉检验，确保获得可操作且可靠的见解。

本报告的调查方法结合了质性访谈、二手文献整合以及严格的交叉检验，以确保分析的平衡性和可靠性。主要见解是透过对兽医、行业高管、研发负责人和分销专家的结构化访谈获得的，这些访谈提供了关于临床应用、产品偏好和物流挑战的真实观点。这些定性资讯与二级资讯来源（包括监管指南、同行评审的科学文献和公开的行业报告）相结合，从而能够对技术和市场趋势进行背景分析。

简明扼要地总结了决定伴侣动物疫苗领域策略成果的关键技术、商业性和区域挑战。

本执行摘要整合了影响伴侣动物疫苗的关键趋势，重点阐述了科学创新、不断变化的饲主期望、不断演变的分销管道以及地缘政治供应因素之间的相互作用。 mRNA疫苗和重组疫苗等技术的成熟，以及灭活疫苗、减毒活病毒疫苗、次单位疫苗和类毒素疫苗平台的持续应用，为研发人员提供了多种选择，以满足尚未满足的需求并提高安全性。随着给药途径偏好和分销管道趋势的同步变化，需要製定协调一致的策略，以确保临床应用和饲主的依从性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：伴侣动物疫苗市场：依动物类型划分

  • 猫
  • 狗

第九章：伴侣动物疫苗市场：依疫苗类型划分

  • 失活
    • 分裂细胞
    • 全细胞
  • 减毒活病毒疫苗
  • mRNA
  • 重组
  • 次单元
  • 类毒素

第十章：伴侣动物疫苗市场：依给药途径划分

  • 黏膜
    • 鼻内
    • 口服
  • 肠外
    • 肌肉内部
    • 皮下

第十一章 伴侣动物疫苗市场：依通路划分

  • 在线的
    • 网路药房
    • 製造商网站
  • 药局
  • 动物诊所
  • 动物医院

第十二章：伴侣动物疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：伴侣动物疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 伴侣动物疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国伴侣动物疫苗市场

第十六章：中国伴侣动物疫苗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Arko Corp.
  • Bimeda Biologicals Inc
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Endovac Animal Health
  • Hester Biosciences Limited
  • Hipra SA
  • Huvepharma, Inc.
  • Indian Immunologicals Ltd.
  • Kemin Industries, Inc.
  • Merck & Co., Inc.
  • Neogen Corporation
  • Pfizer, Inc.
  • Phibro Animal Health Corporation
  • SAN Group BIoTech Germany GmbH
  • Seppic by Air Liquide Healthcare
  • SK Bioscience
  • Vaxxinova
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-957C47F94D1F

The Companion Animal Vaccine Market was valued at USD 5.39 billion in 2025 and is projected to grow to USD 5.85 billion in 2026, with a CAGR of 8.48%, reaching USD 9.54 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.39 billion
Estimated Year [2026] USD 5.85 billion
Forecast Year [2032] USD 9.54 billion
CAGR (%) 8.48%

Comprehensive introduction to the evolving companion animal vaccine environment where scientific innovation converges with owner expectations and clinical practice shifts

The companion animal vaccine landscape sits at an intersection of scientific advancement, shifting owner expectations, and evolving clinical practice. Contemporary stakeholders operate in an environment where both preventive care philosophy and therapeutic innovation shape vaccination strategies for cats and dogs, influencing clinic workflows and supply chain dynamics. Veterinary professionals increasingly integrate diagnostic screening, individualized vaccine protocols, and risk-based recommendations into routine care, prompting manufacturers and distributors to reassess product portfolios and communication tactics.

As consumer awareness of animal health grows, pet owners demand clearer evidence of vaccine safety and benefit, while digital channels accelerate access to educational content and purchasing options. Concurrently, research breakthroughs in platform technologies such as mRNA and recombinant systems are expanding the range of antigen targets and enabling improved immunogenicity and manufacturing efficiencies. These developments prompt manufacturers to balance legacy product support for inactivated and live attenuated vaccines with investment in next-generation modalities.

In addition, the route of administration and the distribution landscape influence both product design and commercial strategy. Mucosal vaccines administered nasally or orally present different acceptance profiles compared with parenteral intramuscular or subcutaneous injections, and online channels including e-pharmacies and manufacturer websites are transforming procurement behaviors. Taken together, these dynamics require an integrated approach to product development, regulatory strategy, and market engagement that aligns scientific opportunity with practical adoption pathways.

In-depth overview of the major technological, behavioral, and clinical shifts reshaping how companion animal vaccines are developed, delivered, and adopted

The companion animal vaccine sector is undergoing transformative shifts driven by technological innovation, changing consumer behaviors, and evolving regulatory and clinical paradigms. Advances in vaccine platforms, notably mRNA and recombinant technologies, are opening new possibilities for targeted immunization strategies, shorter development cycles, and adaptable manufacturing processes capable of responding to emergent disease threats. These scientific advancements are redefining product roadmaps and prompting incumbent manufacturers to re-evaluate R&D priorities and strategic partnerships.

Simultaneously, the role of digital engagement continues to expand. Pet owners now access veterinary information, make purchasing decisions, and seek telehealth consultations through online portals, influencing the prominence of e-pharmacies and manufacturer direct-sales channels. This shift compels stakeholders to develop integrated omni-channel strategies that combine educational outreach, transparent efficacy and safety data, and streamlined purchasing experiences to build trust and foster adherence to vaccination schedules.

Moreover, changing societal views on preventive healthcare for pets and rising expectations around convenience and individualized care are reshaping clinical practice. Veterinarians are increasingly employing risk-based vaccination protocols, leveraging diagnostic tools to tailor immunization plans for individual animals, and prioritizing vaccine types and routes that optimize compliance and minimize adverse events. Together, these factors constitute a structural shift in how vaccines are developed, distributed, and recommended, creating both challenges and opportunities for innovators and service providers across the value chain.

Comprehensive analysis of the cumulative repercussions of United States tariff measures in 2025 on supply chains, manufacturing decisions, and commercial channel economics for companion vaccines

In 2025, tariff measures implemented by the United States introduced an added layer of complexity for manufacturers, distributors, and clinical end users within the companion animal vaccine ecosystem. Tariffs influence cost structures across imported raw materials, finished vaccines, and specialized equipment, thereby altering supply chain decisions and encouraging re-evaluation of manufacturing footprints. Some stakeholders accelerated nearshoring and diversified supplier portfolios to mitigate exposure to trade-related cost volatility, while others sought contractual hedges that preserved access to critical inputs.

These trade policy adjustments also impacted commercial planning and pricing strategies across distribution channels. Veterinary hospitals and clinics that source vaccines internationally reevaluated procurement cycles and supplier terms to maintain predictable inventory levels. Online pharmacies and manufacturer direct channels responded by adjusting their sourcing mixes and logistics arrangements to sustain delivery timelines and service levels to pet owners. In parallel, regulatory compliance and customs administration became more salient considerations during product launches and cross-border distribution discussions.

Furthermore, the tariff-driven recalibration of supply chains prompted renewed attention to domestic manufacturing capabilities and public-private partnerships that support biomanufacturing resilience. Investors and strategic leaders began to weigh the benefits of building local capacity against the capital requirements and timeframes involved, prioritizing technologies that offer flexible production scales. Collectively, these adjustments reflect a broader industry imperative to enhance supply chain robustness, reduce single-source dependencies, and align commercial models with an environment of elevated trade uncertainty.

Actionable segmentation intelligence illuminating how animal type, vaccine platform, administration route, and distribution channel intersect to shape product and commercialization strategies

Segmentation insights reveal how demand drivers, clinical preferences, and channel behaviors vary across animal type, vaccine platform, administration route, and distribution pathways. When considering animal type, cats and dogs display distinct epidemiological and husbandry profiles that shape vaccine prioritization, dosing schedules, and owner counseling. Vaccination strategies for dogs often emphasize core and lifestyle vaccines aligned with outdoor exposure and social interactions, whereas feline protocols prioritize disease risks aligned with indoor/outdoor status and multi-cat household dynamics.

Diving into vaccine type, inactivated platforms and live attenuated vaccines remain well-established for a variety of indications, with inactivated formulations further differentiated into split cell and whole cell options that influence immunogenicity and reactogenicity considerations. Emerging modalities such as mRNA and recombinant vaccines are creating opportunities to target diseases with greater precision and to design antigen constructs that optimize immune response while potentially reducing adverse events. Subunit and toxoid vaccines continue to play critical roles for specific pathogens where targeted antigen presentation or neutralization of toxins is essential.

Route of administration is another vital differentiator, with mucosal options delivered nasally or orally offering non-invasive alternatives to parenteral intramuscular and subcutaneous injections and enabling unique immunological profiles. Distribution channel dynamics further influence access and adoption; online channels comprised of e-pharmacies and manufacturer websites, along with more traditional outlets such as pharmacies, veterinary clinics, and veterinary hospitals, present differing customer journeys and regulatory considerations. Understanding how these segmentation axes intersect is essential for designing product portfolios, clinical guidance, and channel strategies that align with stakeholder expectations and operational realities.

Strategic regional insights into how diverse regulatory regimes, veterinary infrastructures, and owner behaviors drive differentiated approaches across global markets

Regional dynamics significantly influence clinical practice norms, regulatory frameworks, and commercial approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, veterinary care infrastructure and owner engagement models support diverse distribution channels, with strong clinic networks and growing digital adoption that enhances outreach and retailing of preventive healthcare solutions. In contrast, Europe, Middle East & Africa exhibits a mosaic of regulatory environments and economic contexts, requiring highly localized regulatory strategies and flexible distribution models that accommodate both advanced veterinary markets and emerging segments.

Asia-Pacific presents a mix of rapid innovation adoption and variable access to veterinary services, where urbanization and rising pet ownership in key markets drive demand for modern vaccine technologies while logistical considerations and regional supply chains influence product availability. Across all regions, cultural attitudes toward companion animals, public health priorities, and veterinary training standards shape how vaccination protocols are recommended and accepted. These regional nuances necessitate tailored market entry strategies, localized clinical evidence packages, and targeted communication campaigns that resonate with veterinarians and pet owners alike.

Ultimately, effective regional planning integrates epidemiological insight with pragmatic supply and distribution models, regulatory navigation, and stakeholder engagement to ensure that vaccine innovations reach the right markets with appropriate supporting materials and service models.

Deep competitive and ecosystem assessment revealing how incumbents, biotech innovators, and service providers shape adoption and commercialization strategies

Competitive dynamics in the companion animal vaccine sector reflect a blend of established incumbents, specialist biotech firms, and emerging innovators. Established manufacturers continue to leverage broad commercial footprints, long-standing relationships with veterinary professionals, and extensive product portfolios that span traditional vaccine platforms. These capabilities support scale, distribution reliability, and deep clinical familiarity, enabling sustained engagement with veterinary networks and institutional buyers.

At the same time, specialist companies and biotech entrants focus on platform innovation, targeting high-value indications and leveraging technologies such as recombinant antigens and mRNA constructs to differentiate on efficacy, safety, and speed-to-market. These players often pursue strategic collaborations with contract manufacturing organizations and academic groups to accelerate development while optimizing capital allocation. Partnerships between large-scale manufacturers and nimble innovators are increasingly common, facilitating combination strategies that pair commercial reach with scientific novelty.

Service providers across the value chain, including contract manufacturers, diagnostic firms, and digital health platforms, play a pivotal role in enabling product development, quality assurance, and customer engagement. Their capabilities in scalable manufacturing, cold chain logistics, and data-driven marketing help translate scientific advances into clinically adopted products. Overall, the competitive landscape favors organizations that combine scientific differentiation, manufacturing resilience, and a deep understanding of veterinary practice dynamics to achieve sustained adoption among clinicians and pet owners.

Clear and prioritized strategic recommendations for leaders focused on platform diversification, supply resilience, channel optimization, and clinical evidence generation

Industry leaders should align strategic priorities around four interconnected actions: invest in platform diversification, fortify supply chain resilience, optimize channel strategies, and deepen clinical engagement. Prioritizing a portfolio approach that balances established inactivated and live attenuated products with investments in mRNA, recombinant, subunit, and toxoid technologies will allow organizations to respond to both current clinical needs and future disease threats. Concurrently, selecting scalable manufacturing partners and considering regional production capabilities can reduce exposure to trade disruptions and support faster market responsiveness.

Equally important is the refinement of distribution strategies to reflect evolving purchaser behaviors. Strengthening digital channels such as e-pharmacies and manufacturer direct-sales platforms should be complemented by reinforced relationships with pharmacies, veterinary clinics, and hospitals to ensure clinical adoption and continuity of care. In addition, tailoring messaging to emphasize route-of-administration benefits, whether mucosal or parenteral, and providing robust clinical evidence will improve veterinarian confidence and owner acceptance.

Finally, leaders should invest in targeted clinical education and real-world evidence generation that supports differentiated product positioning and informs risk-based vaccination protocols. Executing these recommendations requires cross-functional coordination across R&D, regulatory, commercial, and supply chain teams to translate strategic intent into measurable adoption outcomes.

Robust mixed-method methodology combining primary stakeholder interviews, secondary evidence synthesis, and cross-validation to ensure actionable and credible insights

The research methodology underpinning this report combines primary qualitative interviews, secondary literature synthesis, and rigorous cross-validation to ensure balanced analysis and credibility. Primary insights were obtained through structured interviews with veterinary practitioners, senior industry executives, R&D leaders, and distribution specialists, providing grounded perspectives on clinical adoption, product preferences, and logistical challenges. These qualitative inputs were synthesized with secondary sources that include regulatory guidance, peer-reviewed scientific literature, and publicly available industry reports to contextualize technological and market trends.

To enhance reliability, findings were cross-validated across multiple stakeholder groups and geographic contexts, with particular attention to differences in clinical practice patterns between developed and emerging veterinary markets. The approach emphasizes transparency in assumptions, clear documentation of data provenance, and adherence to ethical standards in primary research engagements. Analytical methods include trend mapping, technology readiness assessment, and channel pathway analysis to illuminate commercialization implications and strategic options for stakeholders.

This methodology ensures that insights are not only descriptive but also actionable, offering decision-makers a robust foundation to evaluate innovation opportunities, distribution choices, and investment priorities within the companion animal vaccine landscape.

Concise conclusion synthesizing technological, commercial, and regional imperatives that determine strategic outcomes in the companion animal vaccine sector

This executive summary synthesizes the essential dynamics shaping companion animal vaccines, underscoring the interplay of scientific innovation, changing owner expectations, distribution evolution, and geopolitical supply considerations. The maturation of technologies such as mRNA and recombinant vaccines, coupled with enduring roles for inactivated, live attenuated, subunit, and toxoid platforms, provides a broad palette for developers to address unmet clinical needs and improve safety profiles. Parallel shifts in route-of-administration preferences and distribution channel behaviors require coordinated strategies to ensure clinical adoption and owner adherence.

Moreover, regional differences across the Americas, Europe, Middle East & Africa, and Asia-Pacific emphasize the importance of localized regulatory navigation and culturally attuned engagement. The cumulative impact of trade policy adjustments highlighted the need for supply chain agility and potential investments in regional manufacturing capabilities. Competitive success will favor organizations that can blend scientific differentiation with commercial scale, resilient operations, and deep partnerships across veterinary networks and digital channels.

In conclusion, stakeholders that proactively align R&D, manufacturing, and commercial strategies while investing in clinical evidence and channel integration will be best positioned to translate innovation into improved animal health outcomes and sustainable business performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Animal Vaccine Market, by Animal Type

  • 8.1. Cats
  • 8.2. Dogs

9. Companion Animal Vaccine Market, by Vaccine Type

  • 9.1. Inactivated
    • 9.1.1. Split Cell
    • 9.1.2. Whole Cell
  • 9.2. Live Attenuated
  • 9.3. mRNA
  • 9.4. Recombinant
  • 9.5. Subunit
  • 9.6. Toxoid

10. Companion Animal Vaccine Market, by Route Of Administration

  • 10.1. Mucosal
    • 10.1.1. Nasal
    • 10.1.2. Oral
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Subcutaneous

11. Companion Animal Vaccine Market, by Distribution Channel

  • 11.1. Online
    • 11.1.1. E Pharmacies
    • 11.1.2. Manufacturer Websites
  • 11.2. Pharmacies
  • 11.3. Veterinary Clinics
  • 11.4. Veterinary Hospitals

12. Companion Animal Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Companion Animal Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Companion Animal Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Companion Animal Vaccine Market

16. China Companion Animal Vaccine Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Arko Corp.
  • 17.6. Bimeda Biologicals Inc
  • 17.7. Biogenesis Bago S.A.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Ceva Sante Animale
  • 17.10. Dechra Pharmaceuticals PLC
  • 17.11. Elanco Animal Health Incorporated
  • 17.12. Endovac Animal Health
  • 17.13. Hester Biosciences Limited
  • 17.14. Hipra S.A.
  • 17.15. Huvepharma, Inc.
  • 17.16. Indian Immunologicals Ltd.
  • 17.17. Kemin Industries, Inc.
  • 17.18. Merck & Co., Inc.
  • 17.19. Neogen Corporation
  • 17.20. Pfizer, Inc.
  • 17.21. Phibro Animal Health Corporation
  • 17.22. SAN Group Biotech Germany GmbH
  • 17.23. Seppic by Air Liquide Healthcare
  • 17.24. SK Bioscience
  • 17.25. Vaxxinova
  • 17.26. Virbac S.A.
  • 17.27. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION ANIMAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPANION ANIMAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 163. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 165. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 166. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 190. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 192. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 193. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 199. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 201. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 202. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)